8-K - BioMarin Pharmaceutical Inc. | StockGist

Current Report Details

Event Type

Financial Results+3 More

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

and accompanying Exhibit 99.1 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the li

Financial Results

7.01

Regulation FD Disclosure. Notes Offering On January 26, 2026, BioMarin issued a press release announcing its intention to offer, subject to market and other con

Regulation Fd

$850.0M$2.00B$800.0M$600.0M

8.01

. Pro Forma Financial Information The company is hereby filing certain unaudited pro forma condensed combined financial information of the company as of and for

Other Event

9.01

Financial Statements and Exhibits. (b) Pro Forma Financial Information The Pro Forma Financial Information is attached as Exhibit 99.3 to this Current Report on

Exhibits Only

Source Document

Exhibits (4)

8-K

99.1

EX-99.1

99.2

EX-99.2

99.3

EX-99.3